Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Taike Bio appears to refer to the Taike biotechnology group centered on Wuhan Taike Biotechnology, with Shenzhen Taike Biotechnology serving as its international sales and purchasing arm. The company is a China-based biotechnology and ingredient manufacturer focused primarily on agar, biotechnological agar, instant agar, seaweed-derived ingredients, and related plant or marine extract products. Its products are sold into food, microbiology, laboratory, plant tissue culture, and broader bioprocessing or industrial applications rather than a therapeutic drug pipeline. Available public information indicates Taike has integrated research, production, and sales capabilities, with operations in the Wuhan Biolake area and commercial reach across multiple global regions. Based on the evidence found, this is better characterized as a commercial biotech materials and ingredients company than a drug-development biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Taike Bio.